Matej Mavrič

Mr. Matej Mavrič


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
GGGašper Grubelnik
Gašper Grubelnik
MKMisa Korva
Misa Korva
RKRok Kogoj
Rok Kogoj
TPTina Polanc
Tina Polanc
MMMatej Mavrič
Matej Mavrič
TATatjana Avsic-Zupanc
Tatjana Avsic-Zupanc
Shortly after the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), cases of viral, bacterial, and fungal coinfections in hospitalized patients became evident. This retrospective study investigates the prevalence of multiple pathogen co-detections in 1472 lower respiratory tract (LRT) samples from 229 SARS-CoV-2-positive patients treated in the largest intensive care unit (ICU) in Slovenia. In addition to SARS-CoV-2, (rt)RT-PCR tests were used to detect cytomegalovirus (CMV), Epstein–Barr virus (EBV), herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), varicella zoster virus (VZV), and atypical bacteria: Chlamydia pneumoniae, Mycoplasma pneumoniae and Legionella pneumophila/spp. At least one co-detection was observed in 89.1% of patients. EBV, HSV-1, and CMV were the most common, with 74.7%, 58.1%, and 38.0% of positive patients, respectively. The median detection time of EBV, HSV-1, and CMV after initial SARS-CoV-2 confirmation was 11 to 20 days. Bronchoalveolar lavage (BAL) and tracheal aspirate (TA) samples showed equivalent performance for the detection of EBV, CMV, and HSV-1 in patients with both available samples. Our results indicate that SARS-CoV-2 infection could be a risk factor for latent herpesvirus reactivation, especially HSV-1, EBV, and CMV. However, additional studies are needed to elucidate the clinical importance of these findings.

3 December 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
NKNina Grasselli Kmet
Nina Grasselli Kmet
MMMatej Mavrič
Matej Mavrič
RSRajko Saletinger
Rajko Saletinger
Background: Patients receiving heart transplantation require lifelong immunosuppression and compared to the general population, they have a more than five times higher chance of acquiring COVID-19, and their mortality rates are higher. The aim of the present study was to estimate the epidemiological and clinical characteristics of COVID-19 in heart transplant recipients (HTRs) in Slovenia to estimate the vaccination rate and evaluate possible vaccination-hesitant subgroups. Methods: All SARS-CoV-2-positive HTRs (N = 79) between 1 March 2020 and 31 December 2023 at the Infectious Diseases Department, University Medical Centre Ljubljana, Slovenia, were included retrospectively. Demographic, clinical and vaccination data were extracted from medical documentation and a statistical evaluation was performed. Results: The observed vaccination rate was 63.3%, but among patients who received transplants before the pandemic, it was statistically significantly higher (p = 0.027). Vaccinated HTRs were statistically significantly older (p = 0.004) and had a significantly higher Charlson Comorbidity Index (p = 0.018). Our results indicate no significant differences between vaccinated and unvaccinated HTRs regarding acute respiratory insufficiency (p = 0.135), length of hospital stay (p = 0.106), intensive care unit admission (0.414) and in-hospital mortality (p = 0.317), but we observed statistically more frequently an asymptomatic course in those vaccinated (p = 0.050), and a longer length of stay in vector vaccine recipients (p = 0.011) and in those not re-vaccinated (p = 0.030). There was a significantly higher re-vaccination rate in males (p = 0.005). Conclusions: An asymptomatic course of COVID-19 was more often observed in vaccinated HTRs. Our findings suggest statistically significant differences in COVID-19 vaccine acceptance rates; younger HTRs and those transplanted after the pandemic are more hesitant to vaccinate, while females accept booster doses less frequently.

6 November 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
NKNina Grasselli Kmet
Nina Grasselli Kmet
MMMatej Mavrič
Matej Mavrič
RSRajko Saletinger
Rajko Saletinger
Background/Objectives: Patients receiving solid organ transplantation require lifelong immunosuppression, making them more susceptible to COVID-19. Vaccination against COVID-19 is recommended for HTR. The aim of the present study was to compare the course of the disease in vaccinated and unvaccinated HTR hospitalized in a tertiary hospital in Slovenia and to evaluate possible hesitant groups. Methods: All SARS-CoV-2 positive HTR (N=79) between 1 March 2020 and 31 December 2023 at the Infectious Diseases Department, University Medical Centre Ljubljana, Slovenia, were included retrospectively. Demographic, clinical and vaccination data were extracted from medical documentation and statistical evaluation was performed. Results: The vaccination rate in the cohort was 63.3%. We found no statistically significant difference in vaccination rates regarding gender (male 68.4% vs. female 50%, p=0.128), but there was a statistically significant higher revaccination rate in males (male 52.7% vs. female 18.2%, p=0.021). Vaccinated HRT were statistically significantly older than unvaccinated (p=0.000) and had a significantly higher Charlson Comorbidity index (p=0.001). The vaccination rate among patients who received transplants before the pandemic (prior to 2020) was statistically significantly higher (71.7% vs. 46.2%; p=0.027). Conclusions: Our results indicate no significant differences in the clinical course of COVID-19 between vaccinated and unvaccinated HRT regarding acute respiratory insufficiency (ARI), length of hospital stay (LOS), intensive care unit admission and mortality. However, our findings do suggest statistically significant differences in COVID-19 vaccine acceptance rates; younger HRT and those transplanted after the pandemic are more hesitant to vaccination and female HRT accept booster doses less frequently.